Literature DB >> 11406756

Nosocomial fungemia due to amphotericin B-resistant Candida spp. in three pediatric patients after previous neurosurgery for brain tumors.

G Kovacicova1, J Hanzen, M Pisarcikova, D Sejnova, J Horn, R Babela, I Svetlansky, M Lovaszova, M Gogova, V Krcmery.   

Abstract

Amphotericin B (AmB) resistance in Candida spp. is very rare. Three cases of fungemia, due to amphotericin B-resistant Candida spp. in pediatric patients after previous neurosurgery for brain tumors, are reported. The Candida strains - one C. guillermondii, one C. lusitaniae, and one C. parapsilosis - showed minimum inhibitory concentrations (MICs) to AmB of 2-4 microg/ml. Two of the three patients had been pretreated with AmB for 5-11 days. All three patients were successfully treated with intravenous fluconazole (6-10 mg/kg per day) for 16-28 days, and all survived. Despite AmB resistance in Candida spp. being very rare, C. lusitaniae, C. guillermondii, and C. parapsilosis isolates in documented infections should be tested for AmB resistance, mainly in patients not responding to therapy with AmB.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11406756     DOI： 10.1007/s101560170033

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN： 1341-321X            Impact factor:   2.211


  9 in total

1.  Killing kinetics of caspofungin, micafungin, and amphotericin B against Candida guilliermondii.

Authors:  Emilia Cantón; Javier Pemán; Macrina Sastre; Mónica Romero; Ana Espinel-Ingroff
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

2.  Candida guilliermondii fungemia in patients with hematologic malignancies.

Authors:  Corrado Girmenia; Giampaolo Pizzarelli; Francesco Cristini; Francesco Barchiesi; Elisabetta Spreghini; Giorgio Scalise; Pietro Martino
Journal:  J Clin Microbiol       Date:  2006-07       Impact factor: 5.948

Review 3.  Candida parapsilosis: from Genes to the Bedside.

Authors:  Renáta Tóth; Jozef Nosek; Héctor M Mora-Montes; Toni Gabaldon; Joseph M Bliss; Joshua D Nosanchuk; Siobhán A Turner; Geraldine Butler; Csaba Vágvölgyi; Attila Gácser
Journal:  Clin Microbiol Rev       Date:  2019-02-27       Impact factor: 26.132

4.  A new look at the antibiotic amphotericin B effect on Candida albicans plasma membrane permeability and cell viability functions.

Authors:  Barbara Chudzik; Mateusz Koselski; Aleksandra Czuryło; Kazimierz Trębacz; Mariusz Gagoś
Journal:  Eur Biophys J       Date:  2015-01-04       Impact factor: 1.733

5.  Usefulness of McRAPD for typing and importance of biofilm production in a case of nosocomial ventriculoperitoneal shunt infection caused by Candida lusitaniae.

Authors:  Petr Hamal; Juraj Hanzen; Frantisek Horn; Jitka Trtkova; Lenka Ruskova; Renata Vecerova; Filip Ruzicka; Anna Vollekova; Vladislav Raclavsky
Journal:  Folia Microbiol (Praha)       Date:  2011-09-06       Impact factor: 2.099

Review 6.  Therapeutic Drug Monitoring of Antifungal Agents in Critically Ill Patients: Is There a Need for Dose Optimisation?

Authors:  Daniela Baracaldo-Santamaría; Juan David Cala-Garcia; Germán José Medina-Rincón; Luis Carlos Rojas-Rodriguez; Carlos-Alberto Calderon-Ospina
Journal:  Antibiotics (Basel)       Date:  2022-05-12

Review 7.  Invasive candidiasis in pediatric intensive care patients: epidemiology, risk factors, management, and outcome.

Authors:  Joanna Filioti; Kleomenis Spiroglou; Emmanuel Roilides
Journal:  Intensive Care Med       Date:  2007-05-15       Impact factor: 17.440

8.  Distribution of yeast-like fungi at a university hospital in Turkey.

Authors:  Gulfem Ece
Journal:  Jundishapur J Microbiol       Date:  2014-12-01       Impact factor: 0.747

9.  Risk assessment for the spread of Candida sp. in dental chair unit waterlines using molecular techniques.

Authors:  Wissame Mazari; Zahia Boucherit-Otmani; Imad Abdelhamid El Haci; Amine Ilahi; Kebir Boucherit
Journal:  Int Dent J       Date:  2018-05-04       Impact factor: 2.607
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.